ArticleJournal of translational medicine2026
Impact of antinuclear and antiphospholipid antibodies on ART outcomes in women with recurrent reproductive failure.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrent reproductive failure (RRF), encompassing repeated implantation failure and pregnancy loss, remains a major challenge in assisted reproductive technology (ART). Autoimmune factors have been implicated in adverse reproductive outcomes, but the combined impact of antinuclear antibodies (ANA) and antiphospholipid antibodies (aPL) on ART success in women with RRF is unclear.
methodsThis retrospective cohort study analyzed 682 women with RRF who underwent IVF or ICSI between April 2019 and April 2024. Participants were classified into four groups based on ANA and aPL status. Clinical characteristics, laboratory indices, and ART outcomes were compared. Univariable and multivariable logistic regression analyses were conducted to identify predictors of live birth.
resultsLive birth rates differed significantly across groups (p = 0.001), with the ANA-/aPL- group showing the highest rate (36.3%) and lower rates in women positive for either or both autoantibodies. Clinical pregnancy rates were also lower in the ANA+/aPL+ group (30.6% vs. 49.8%, p = 0.050). Multivariable analysis confirmed ANA positivity (adjusted OR 0.57, 95% CI 0.38-0.86) and longer infertility duration as independent predictors of reduced live birth rates. No significant differences were observed between single and multiple ANA specificities in terms of reproductive outcomes.
conclusionsThe concurrent presence of ANA and aPL is associated with significantly poorer IVF outcomes in women with unexplained RRF. These findings suggest that comprehensive autoantibody profiling may help identify a specific high-risk subset of RRF patients. Further prospective studies are warranted to determine whether this subgroup benefits from targeted immunomodulatory interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.